Veerhealth Care Ltd (BSE: 511523) announced today that it has commenced execution and received additional export orders from its US client, following USFDA approval of its facility earlier this year.
In a regulatory filing on 22 July 2025, the company stated it has already completed three full-container-load (FCL) shipments to the US since receiving USFDA clearance in May 2025. With new orders now in hand, Veerhealth aims to dispatch 4–5 shipments per month going forward, which is expected to strengthen its revenue streams and presence in the regulated US market.
The company also revealed it is in discussions with a major Russian corporate group for exporting oral care products to Russia and expects to enter that market soon.
Commenting on the achievement, Managing Director Bhavin S. Shah said:
“Securing significant repeat orders from a US client highlights the quality and reliability of our products. This milestone not only boosts our current standing but also enhances our reputation in global markets. We are operating at full capacity to meet increased domestic and export demand and expect strong revenue and profitability growth in the coming quarters.”
Veerhealth expects to achieve revenues of ₹35–40 crore with a 10% PAT in FY25–26 and has set a target of ₹100 crore revenue over the next 2–3 years. The company is also advancing plans to expand into the medical device category in the US, working on the formalities with the USFDA.
About Veerhealth Care Ltd
Veerhealth manufactures Ayurvedic medicines, oral care, and personal care products under its brand Ayuveer. Its operations include contract manufacturing, white labelling, product R&D, and customised formulations. The company also runs divisions focused on hospital care equipment and high-quality toothbrushes through its VeerPlast brand.
